A Multicentre Study of the Efficacy and Safety of Supplementary Treatment With Cholecalciferol in Patients With Relapsing Multiple Sclerosis Treated With Subcutaneous Interferon Beta-1a 44 µg 3 Times Weekly

NCT01198132 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

129

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Sclerosis

Interventions

DIETARY_SUPPLEMENT: Cholecalciferol (Vitamin D3)
DIETARY_SUPPLEMENT: Placebo
DRUG: Rebif

Sponsor

Merck KGaA, Darmstadt, Germany

Collaborators

[object Object]